MIRATI THERAPEUTICS INC (MRTX) Stock Price, Quote, News and Overview
NASDAQ:MRTX - Nasdaq - US60468T1051 - Common Stock - Currency: USD
MRTX Quote, Performance and Key Statistics
MIRATI THERAPEUTICS INC
NASDAQ:MRTX (1/22/2024, 8:00:02 PM)
After market: 58.99 +0.29 (+0.49%)58.7
-0.1 (-0.17%)
The current stock price of MRTX is 58.7 USD. In the past month the price decreased by -0.44%. In the past year, price increased by 10.57%.
MRTX Latest News, Press Releases and Analysis
Bristol Myers stock cut at Redburn Atlantic (NYSE:BMY)
Redburn Atlantic downgrades Bristol-Myers Squibb (BMY) due to headwinds against its products despite the company's recent buyout deals. Read more here.
Billionaire Joe Lewis Nets 730% Gain on Stock Behind US Charges
British billionaire Joe Lewis has sold his stake in a biotechnology firm at the center of the US insider-trading case in which he pleaded guilty this week, cementing an eight-fold gain.
Bristol Myers Squibb completes Mirati acquisition (NYSE:BMY)
Bristol Myers Squibb (BMY) closes its acquisition of Mirati Therapeutics (MRTX) and sees $0.35 per share adj. earnings impact from the deal. Read more here.
Bristol Myers Squibb closes Mirati acquisition (NYSE:BMY)
Bristol Myers Squibb (BMY) closes its acquisition of Mirati Therapeutics (MRTX) and sees $0.35 per share adj. earnings impact from the deal. Read more here.
Mirati's Krazati gets EU conditional approval for lung cancer (NASDAQ:MRTX)
Mirati (MRTX) receives EU conditional approval for its drug Krazati in the treatment of lung cancer with KRAS G12C mutations. Read more here.
Bristol-Myers looking for smaller deals after 2023 shopping spree: report (NYSE:BMY)
Bristol Myers Squibb (BMY) reportedly expects to launch 16 new products by the end of the decade, but will be looking for smaller deals after its 2023 shopping
MRTX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About MRTX
Company Profile
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. The company is headquartered in San Diego, California and currently employs 587 full-time employees. The company went IPO on 2013-07-12. The firm is developing novel therapeutics to address the genetic and immunological promoters of cancer. The firm's product KRAZATI is an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Its MRTX1133 is an investigational, selective, and potent KRAS G12D inhibitor. Its MRTX1719 is an investigational synthetic lethal PRMT5 inhibitor designed to specifically target the PRMT5/ methylthioadensoine (MTA) complex. Its MRTX0902 is a potent, selective SOS1 inhibitor, designed to improve anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors. Its Sitravatinib is an investigational spectrum-selective kinase inhibitor designed to potently inhibit receptor tyrosine kinases (RTKs) and enhance immune responses through the inhibition of immunosuppressive signaling.
Company Info
MIRATI THERAPEUTICS INC
3545 Cray Court
San Diego CALIFORNIA 92121 US
CEO: Charles M. Baum
Employees: 587
Company Website: https://www.mirati.com/
Phone: 18583323410
MRTX FAQ
What is the stock price of MRTX?
The current stock price of MRTX is 58.7 USD.
What is the symbol for MIRATI THERAPEUTICS INC stock?
The exchange symbol of MIRATI THERAPEUTICS INC is MRTX and it is listed on the Nasdaq exchange.
On which exchange is MRTX stock listed?
MRTX stock is listed on the Nasdaq exchange.
Is MRTX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for MRTX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of MRTX.
Does MRTX stock pay dividends?
MRTX does not pay a dividend.
When does MRTX stock report earnings?
MRTX will report earnings on 2024-02-26, after the market close.
What is the Price/Earnings (PE) ratio of MRTX?
MRTX does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.22).
MRTX Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to MRTX. When comparing the yearly performance of all stocks, MRTX turns out to be only a medium performer in the overall market: it outperformed 69.11% of all stocks.
MRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MRTX. While MRTX has a great health rating, there are worries on its profitability.
MRTX Financial Highlights
Over the last trailing twelve months MRTX reported a non-GAAP Earnings per Share(EPS) of -12.22. The EPS decreased by 8.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| Debt/Equity | 0 |
MRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 69% to MRTX. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 14.07% and a revenue growth 406.04% for MRTX